General description
Insulin-like growth factor 2 mRNA-binding protein 2 (UniProt: Q9Y6M1; also known as IGF2 mRNA-binding protein 2; IMP-2, Hepatocellular carcinoma autoantigen p62, IGF-II mRNA-binding protein 2, VICKZ family member 2) is encoded by the IGF2BP2 (also known as IMP2, VICKZ2) gene (Gene ID: 10644) in human. IGF2BP2 is a multifunctional RNA-binding protein that coordinates post-transcriptional gene regulation by coupling sequence/structure recognition to mRNA stabilization, storage, localization, and translation, with prominent roles in metabolic homeostasis and cancer. IGF2BP2 contains two N-terminal RNA recognition motifs (RRM1–2) followed by four K-homology domains (KH1–KH4) that provide the dominant RNA-binding surface and target selectivity. The KH3–KH4 di-domain is particularly important for m6A-associated RNA recognition, while other RNA-binding modules can contribute accessory binding and regulation. In the cytoplasm, IGF2BP2 operates in ribonucleoprotein (RNP) assemblies and stress-responsive compartments, consistent with its ability to protect bound transcripts from decay and to promote translation in an m6A-dependent manner.
The foundational study establishing IGF2BPs as m6A “readers” showed that IGF2BP family binding enhances mRNA stability and translation and shifts with stress/recovery in ways consistent with storage/translation cycling. IGF2BP2 is broadly expressed with predominantly cytoplasmic localization across many tissues and cell types. IGF2BP2 engages an interaction network of RBPs that likely implements cooperative stabilization/translation control; proteomics in the m6A-reader study identified cofactors including ELAVL1 (HuR), MATR3, and PABPC1 in IGF2BP2 complexes, supporting a model in which IGF2BP2 recruits stabilizing/translation-promoting machinery to methylated transcripts. IGF2BP2 is widely implicated in tumor biology through m6A-dependent stabilization of oncogenic and pro-metastatic transcripts. Variations in the IGF2BP2 gene may affect fetal glucose metabolism and plays a role in type 2 diabetes. This ZooMAb® recombinant monoclonal antibody, generated by our proprietary technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals.
ZooMAb® antibodies represent an entirely new generation of recombinant monoclonal antibodies. Each ZooMAb® antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb® antibodies are reliably available and ready to ship when you need them.
This product aligns with one or more of the 12 Principles of Green Chemistry. This antibody is preservative-free, produced without the harm or sacrifice of animals, and exceptionally stable to allow for ambient shipping and storage, and thus aligns with Green Chemistry Principles ′Waste Prevention′, ′Designing Safer Chemicals′, and ′Design for Energy Efficiency′.
Immunogen
KLH-conjugated linear peptide corresponding to 24 amino acids from the N-terminal half of human IGF2BP2.
Application
Quality Control Testing
Evaluated by Western Blotting in HT-1080 cell lysate.
Western Blotting Analysis: A 1:1,000 dilution of this antibody detected IGF2BP2 in HT-1080 cell lysate.
Tested Applications
Immunocytochemistry Analysis: A 1:100 dilution from a representative detected IGF2BP2 in HepG2 cells.
Immunohistochemistry (Paraffin) Analysis: A 1:100 dilution from a representative lot detected IGF2BP2 in human colon cancer tissue sections.
Affinity Binding Assay: A representative lot of this antibody bound with IGF2BP2 peptide with at least ten thousand-fold (10,000X) higher affinity than with non-specific control peptide.
Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user.
Biochem/physiol Actions
Clone 5D13 is a ZooMAb® rabbit recombinant monoclonal antibody that detects IGF2BP2. It targets an epitope within 24 amino acids from the N-terminal half.
Physical form
Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS with 5% Trehalose, normal appearance a coarse or translucent resin. The PBS/trehalose components in the ZooMAb formulation can have the appearance of a semi-solid (bead like gel) after lyophilization. This is a normal phenomenon. Please follow the recommended reconstitution procedure in the data sheet to dissolve the semi-solid, bead-like, gel-appearing material. The resulting antibody solution is completely stable and functional as proven by full functional testing. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 µL.
Preparation Note
300 µg/mL after reconstitution at 25 µL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.
Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 µL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.
Legal Information
ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.